Close

Cellectis introduces human iPS derived hepatocyte product

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Revolutionizing Pharma Manufacturing with Biofermentation

Synthetic Chemistry and Integrated Biofermentation Transformational Pharmaceutical Manufacturing Combining biofermentation...

Cellectis stem cells, a business unit of Cellectis Group, has introduced hiPS-HEP, a human iPS derived hepatocyte product.

The hiPS-HEP, with homogeneity, a long life span of stable CYP activity and reproducibility, provides a range of in vitro applications such as drug discovery, toxicity testing and vaccine development.

Cellectis stem cells CSO Johan Hyllner said due to their high relevance in various industrial applications it makes the hiPS-HEP a promising system for research and development.

“The pharmaceutical industry has a great need for better and more clinically relevant models early in the drug development process to predict hepatotoxicity, find new drug targets and develop new vaccines,” Hyllner added. Under quality controlled and ethically approved procedures, the human hepatocyte-like cells are derived from human induced Pluripotent Stem (iPS) cells.

Latest stories

Related stories

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Revolutionizing Pharma Manufacturing with Biofermentation

Synthetic Chemistry and Integrated Biofermentation Transformational Pharmaceutical Manufacturing Combining biofermentation...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back